Filtered By:
Condition: Food Allergy
Management: Funding

This page shows you your search results in order of date.

Order by Relevance | Date

Total 20 results found since Jan 2013.

Food allergy drug developer Alladapt raises $119M in new funding
A developer of a drug designed to treat a variety of food allergies raised $119 million as it prepares for a potentially pivotal clinical trial. Alladapt Immunotherapeutics Inc. announced the new funding deal Wednesday. Patient Square Capital's Enavate Sciences unit led the round. Founding investor Gurnet Point Capital and new investors AllerFund, Novartis AG, Red Tree Venture Capital and WestRiver Group participated in the deal. The Menl o Park company had previously raised a total of $63 million…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 23, 2022 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Food allergy drug developer Alladapt raised $119M in new funding
A developer of a drug designed to treat a variety of food allergies raised $119 million as it prepares for a potentially pivotal clinical trial. Alladapt Immunotherapeutics Inc. announced the new funding deal Wednesday. Patient Square Capital's Enavate Sciences unit led the round. Founding investor Gurnet Point Capital and new investors AllerFund, Novartis AG, Red Tree Venture Capital and WestRiver Group participated in the deal. The Menl o Park company had previously raised a total of $63 million…
Source: bizjournals.com Health Care:Physician Practices headlines - June 22, 2022 Category: American Health Authors: Ron Leuty Source Type: news

Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 -- (Heal... Biopharmaceuticals, Venture Capital Ukko, Bayer, food allergy
Source: HSMN NewsFeed - January 27, 2021 Category: Pharmaceuticals Source Type: news

‘This Is Really Life or Death.’ For People With Disabilities, Coronavirus Is Making It Harder Than Ever to Receive Care
Jeiri Flores is normally a busy, upbeat 29-year-old. But amid the COVID-19 pandemic, her go-to thought has been dark. “If I get this,” she thinks, “I’m gonna die.” This is not an unfounded fear. Flores has cerebral palsy, uses a wheelchair and needs assistance with everyday tasks, including making food and getting dressed. Her disability means it’s tougher for her immune system to kick illnesses; she’s still recovering from a bout of pneumonia she had in January. So beating COVID-19 could easily mean a protracted battle and months in a hospital—a prospect that comes with a c...
Source: TIME: Health - April 24, 2020 Category: Consumer Health News Authors: Abigail Abrams Tags: Uncategorized COVID-19 Source Type: news

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial
Publication date: Available online 19 February 2020Source: The LancetAuthor(s): Håvard Ove Skjerven, Eva Maria Rehbinder, Riyas Vettukattil, Marissa LeBlanc, Berit Granum, Guttorm Haugen, Gunilla Hedlin, Linn Landrø, Benjamin J Marsland, Knut Rudi, Kathrine Dønvold Sjøborg, Cilla Söderhäll, Anne Cathrine Staff, Kai-Håkon Carlsen, Anna Asarnoj, Karen Eline Stensby Bains, Oda C Lødrup Carlsen, Kim M Advocaat Endre, Peder Annæus Granlund, Johanne Uthus HermansenSummaryBackgroundSkin emollients applied during early infancy could prevent atopic dermatitis, and early complementary food introduction might reduce food all...
Source: The Lancet - February 21, 2020 Category: General Medicine Source Type: research

Startup gobbles up $60M from high-profile investors to target food allergies
A narrow band of proteins that run through dozens of food allergies helped a Peninsula startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical trial later t his year. The oral drug is designed to provoke an immune…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 20, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Human Gut-Associated Natural Killer Cells in Health and Disease
Alessandro Poggi1*, Roberto Benelli2, Roberta Venè1, Delfina Costa1, Nicoletta Ferrari1, Francesca Tosetti1 and Maria Raffaella Zocchi3 1Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy 2Immunology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy 3Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy It is well established that natural killer (NK) cells are involved in both innate and adaptive immunity. Indeed, they can recognize molecules induced at the cell surface by stress signals...
Source: Frontiers in Immunology - May 2, 2019 Category: Allergy & Immunology Source Type: research

Pro-Con Debate: Component resolved diagnostic testing is not useful for making food allergy diagnoses
Funding: none
Source: Annals of Allergy, Asthma and Immunology - February 14, 2019 Category: Allergy & Immunology Authors: Matthew Greenhawt. Tags: Perspective Source Type: research

Funding will help uncover immune system differences that trigger food allergies
(Children's National Health System) Adora A. Lin, M.D., Ph.D., an attending physician in Children's department of Allergy and Immunology, was awarded $240,000 to improve understanding of how children's immune systems tolerate or react to certain food allergens -- sometimes triggering a cascade of side effects that can be fatal.
Source: EurekAlert! - Medicine and Health - April 13, 2018 Category: International Medicine & Public Health Source Type: news

Erratum to: Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review
Unfortunately this article [1] was published with an error in the Funding section. The BM4SIT project is not acknowledged. This section should be corrected to the below:FundingEAACI and the BM4SIT project (Grant Number 601763) in the European Union ’s Seventh Framework Programme FP7.
Source: Clinical and Translational Allergy - September 15, 2017 Category: Allergy & Immunology Source Type: research

NIH designates $42.7 million for food allergy research consortium
(NIH/National Institute of Allergy and Infectious Diseases) The National Institutes of Health intends to award $42.7 million over seven years to the Consortium of Food Allergy Research (CoFAR) so it may continue evaluating new approaches to treat food allergy. Established in 2005, the CoFAR has been continuously funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH. The first year of funding has been awarded, and awards will be made in subsequent years based on the availability of funds.
Source: EurekAlert! - Medicine and Health - March 29, 2017 Category: Global & Universal Source Type: news